{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:48:20Z","timestamp":1792601300304,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007333","name":"Alzheimer's Disease Neuroimaging Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007333","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015725","name":"IXICO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005061","name":"Innogenetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006775","name":"GE Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG024904"],"award-info":[{"award-number":["U01 AG024904"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007050","name":"Medpace","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroscience Methods"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jneumeth.2022.109581","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T12:34:35Z","timestamp":1648211675000},"page":"109581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Categorical predictive and disease progression modeling in the early stage of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"374","author":[{"given":"Carlos","family":"Platero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneumeth.2022.109581_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimeras Association guidelines for the neuropathologic assessment of Alzheimeras disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.jneumeth.2022.109581_bib2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.neurobiolaging.2009.04.002","article-title":"Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease","volume":"30","author":"Price","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jneumeth.2022.109581_bib3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneumeth.2022.109581_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jneumeth.2022.109581_bib5","first-page":"108","article-title":"Cognitive impairment and decline in cognitively normal older adults with high amyloid-\u03b2: a meta-analysis","volume":"6","author":"Baker","year":"2017","journal-title":"Alzheimer Dement.: Diagn., Assess. Dis. Monit."},{"key":"10.1016\/j.jneumeth.2022.109581_bib6","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","article-title":"Determining clinically meaningful decline in preclinical Alzheimer disease","volume":"93","author":"Insel","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jneumeth.2022.109581_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimeras disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.jneumeth.2022.109581_bib8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","article-title":"Duration of preclinical, prodromal, and dementia stages of Alzheimeras disease in relation to age, sex, and APOE genotype","volume":"15","author":"Vermunt","year":"2019","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.jneumeth.2022.109581_bib9","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1002\/hbm.22810","article-title":"Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer\u2019s disease","volume":"36","author":"Soldan","year":"2015","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.jneumeth.2022.109581_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jalz.2016.07.151","article-title":"Progression from normal cognition to mild cognitive impairment in a diverse clinic-based and community-based elderly cohort","volume":"13","author":"Chen","year":"2017","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.jneumeth.2022.109581_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0459-7","article-title":"Prevalence and risk of progression of preclinical Alzheimer\u2019s disease stages: a systematic review and meta-analysis","volume":"11","author":"Parnetti","year":"2019","journal-title":"Alzheimer Res. Ther."},{"key":"10.1016\/j.jneumeth.2022.109581_bib12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ana.22628","article-title":"An operational approach to National Institute on Aging-Alzheimer\u2019s Association criteria for preclinical Alzheimer disease","volume":"71","author":"Jack","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneumeth.2022.109581_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","article-title":"Preclinical Alzheimer\u2019s disease and its outcome: a longitudinal cohort study","volume":"12","author":"Vos","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneumeth.2022.109581_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-150128","article-title":"Subtle cognitive decline and biomarker staging in preclinical Alzheimer\u2019s disease","volume":"47","author":"Edmonds","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.jneumeth.2022.109581_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168011","article-title":"Early prediction of Alzheimer\u2019s disease using null longitudinal model-based classifiers","volume":"12","author":"Gavidia-Bovadilla","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.jneumeth.2022.109581_bib16","first-page":"147","article-title":"A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium","volume":"8","author":"Gross","year":"2017","journal-title":"Alzheimer Dement.: Diagn., Assess. Dis. Monit."},{"key":"10.1016\/j.jneumeth.2022.109581_bib17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/brain\/awx365","article-title":"Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years","volume":"141","author":"Albert","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.jneumeth.2022.109581_bib18","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3233\/JAD-170769","article-title":"A \u2018framingham-like\u2019 algorithm for predicting 4-year risk of progression to amnestic mild cognitive impairment or Alzheimer\u2019s disease using multidomain information","volume":"63","author":"Steenland","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.jneumeth.2022.109581_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-019-0487-y","article-title":"Personalized risk for clinical progression in cognitively normal subjects\u2013the ABIDE project","volume":"11","author":"van Maurik","year":"2019","journal-title":"Alzheimer Res. Ther."},{"key":"10.1016\/j.jneumeth.2022.109581_bib20","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/alz.12140","article-title":"AD risk score for the early phases of disease based on unsupervised machine learning","volume":"16","author":"Wang","year":"2020","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.jneumeth.2022.109581_bib21","doi-asserted-by":"crossref","unstructured":"Luo, W., Wen, H., Ge, S., Tang, C., Liu, X., Lu, L., 2021, Development of a sex-specific risk scoring system for predicting cognitive normal to mild cognitive impairment (srss-cnmci).","DOI":"10.21203\/rs.3.rs-517520\/v1"},{"key":"10.1016\/j.jneumeth.2022.109581_bib22","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneumeth.2022.109581_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40708-015-0027-x","article-title":"Automated identification of dementia using medical imaging: a survey from a pattern classification perspective","volume":"3","author":"Zheng","year":"2016","journal-title":"Brain Inform."},{"key":"10.1016\/j.jneumeth.2022.109581_bib24","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.neuroimage.2017.03.057","article-title":"A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimeras disease and its prodromal stages","volume":"155","author":"Rathore","year":"2017","journal-title":"NeuroImage"},{"key":"10.1016\/j.jneumeth.2022.109581_bib25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11065-017-9366-0","article-title":"Detectable neuropsychological differences in early preclinical Alzheimer\u2019s disease: A meta-analysis","volume":"27","author":"Han","year":"2017","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.jneumeth.2022.109581_bib26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.neuroimage.2012.10.065","article-title":"Statistical analysis of longitudinal neuroimage data with linear mixed effects models","volume":"66","author":"Bernal-Rusiel","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.jneumeth.2022.109581_bib27","article-title":"Predicting progression from mild cognitive impairment to Alzheimeras disease using autoregressive modelling of longitudinal and multimodal biomarkers","author":"Minhas","year":"2017","journal-title":"IEEE J. Biomed. Health Inform."},{"key":"10.1016\/j.jneumeth.2022.109581_bib28","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.neuroimage.2005.05.015","article-title":"Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study","volume":"27","author":"Ch\u00e9telat","year":"2005","journal-title":"Neuroimage"},{"key":"10.1016\/j.jneumeth.2022.109581_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.neuroimage.2014.10.002","article-title":"Machine learning framework for early MRI-based Alzheimer\u2019s conversion prediction in MCI subjects","volume":"104","author":"Moradi","year":"2015","journal-title":"Neuroimage"},{"key":"10.1016\/j.jneumeth.2022.109581_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138866","article-title":"Predicting progression from mild cognitive impairment to Alzheimer\u2019s dementia using clinical, MRI, and plasma biomarkers via probabilistic pattern classification","volume":"11","author":"Korolev","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jneumeth.2022.109581_bib31","series-title":"Survival Analysis. Volume 3","author":"Kleinbaum","year":"2010"},{"key":"10.1016\/j.jneumeth.2022.109581_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neuroimage.2014.04.015","article-title":"Event time analysis of longitudinal neuroimage data","volume":"97","author":"Sabuncu","year":"2014","journal-title":"NeuroImage"},{"key":"10.1016\/j.jneumeth.2022.109581_bib33","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1016\/j.jalz.2013.10.003","article-title":"Estimating long-term multivariate progression from short-term data","volume":"10","author":"Donohue","year":"2014","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.jneumeth.2022.109581_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuroimage.2016.06.049","article-title":"Instantiated mixed effects modeling of Alzheimeras disease markers","volume":"142","author":"Guerrero","year":"2016","journal-title":"NeuroImage"},{"key":"10.1016\/j.jneumeth.2022.109581_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153040","article-title":"Learning biomarker models for progression estimation of Alzheimer\u2019s disease","volume":"11","author":"Schmidt-Richberg","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jneumeth.2022.109581_bib36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/0962280217737566","article-title":"Bayesian latent time joint mixed effect models for multicohort longitudinal data","volume":"28","author":"Li","year":"2019","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.jneumeth.2022.109581_bib37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuroimage.2017.08.059","article-title":"Probabilistic disease progression modeling to characterize diagnostic uncertainty: application to staging and prediction in Alzheimeras disease","volume":"190","author":"Lorenzi","year":"2019","journal-title":"NeuroImage"},{"key":"10.1016\/j.jneumeth.2022.109581_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneumeth.2022.109581_bib39","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.neuroimage.2012.01.062","article-title":"An event-based model for disease progression and its application in familial Alzheimeras disease and Huntingtonas disease","volume":"60","author":"Fonteijn","year":"2012","journal-title":"NeuroImage"},{"key":"10.1016\/j.jneumeth.2022.109581_bib40","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1093\/brain\/awu176","article-title":"A data-driven model of biomarker changes in sporadic Alzheimeras disease","volume":"137","author":"Young","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.jneumeth.2022.109581_bib41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.neuroimage.2018.11.024","article-title":"Disease progression timeline estimation for Alzheimeras disease using discriminative event based modeling","volume":"186","author":"Venkatraghavan","year":"2019","journal-title":"NeuroImage"},{"key":"10.1016\/j.jneumeth.2022.109581_bib42","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jalz.2012.06.004","article-title":"Standardization of analysis sets for reporting results from ADNI MRI data","volume":"9","author":"Wyman","year":"2013","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.jneumeth.2022.109581_bib43","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jalz.2015.05.007","article-title":"Introduction to special issue: overview of Alzheimeras Disease Neuroimaging Initiative","volume":"11","author":"Weiner","year":"2015","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.jneumeth.2022.109581_bib44","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jalz.2013.05.1769","article-title":"The Alzheimeras Disease Neuroimaging Initiative: a review of papers published since its inception","volume":"9","author":"Weiner","year":"2013","journal-title":"Alzheimer Dement.: J. Alzheimer Assoc."},{"key":"10.1016\/j.jneumeth.2022.109581_bib45","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.neurobiolaging.2014.04.034","article-title":"Structural imaging biomarkers of Alzheimer\u2019s disease: predicting disease progression","volume":"36","author":"Eskildsen","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jneumeth.2022.109581_bib46","unstructured":"Anonthe ADNI team: ADNIMERGE: Alzheimer\u2019s Disease Neuroimaging Initiative. (2021)R package version 0.0.1."},{"key":"10.1016\/j.jneumeth.2022.109581_bib47","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimeras disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.jneumeth.2022.109581_bib48","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","article-title":"Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of \u03b2 -amyloid (1-42) in human cerebrospinal fluid","volume":"12","author":"Bittner","year":"2016","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.jneumeth.2022.109581_bib49","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","article-title":"The preclinical Alzheimer cognitive composite: measuring amyloid-related decline","volume":"71","author":"Donohue","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneumeth.2022.109581_bib50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.nicl.2016.12.011","article-title":"Reyas Auditory Verbal Learning Test scores can be predicted from whole brain MRI in Alzheimeras disease","volume":"13","author":"Moradi","year":"2017","journal-title":"NeuroImage: Clin."},{"key":"10.1016\/j.jneumeth.2022.109581_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2020.108698","article-title":"Longitudinal survival analysis and two-group comparison for predicting the progression of mild cognitive impairment to Alzheimer\u2019s disease","volume":"341","author":"Platero","year":"2020","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.jneumeth.2022.109581_bib52","series-title":"Applied Predictive Modeling","volume":"Volume 26","author":"Kuhn","year":"2013"},{"key":"10.1016\/j.jneumeth.2022.109581_bib53","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1109\/TPAMI.2005.159","article-title":"Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy","volume":"27","author":"Peng","year":"2005","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"10.1016\/j.jneumeth.2022.109581_bib54","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.neuroimage.2010.06.013","article-title":"Automatic classification of patients with Alzheimeras disease from structural MRI: a comparison of ten methods using the ADNI database","volume":"56","author":"Cuingnet","year":"2011","journal-title":"neuroimage"},{"key":"10.1016\/j.jneumeth.2022.109581_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40708-019-0099-0","article-title":"Predicting the course of Alzheimeras progression","volume":"6","author":"Iddi","year":"2019","journal-title":"Brain Inform."},{"key":"10.1016\/j.jneumeth.2022.109581_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","article-title":"Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials","volume":"30","author":"Sevigny","year":"2016","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.jneumeth.2022.109581_bib57","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1212\/WNL.0000000000003126","article-title":"Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration","volume":"87","author":"Wolz","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jneumeth.2022.109581_bib58","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.trci.2017.08.005","article-title":"The effect of diagnostic criteria on outcome measures in preclinical and prodromal alzheimeras disease: implications for trial design","volume":"3","author":"Bertens","year":"2017","journal-title":"Alzheimer Dement.: Transl. Res. Clin. Interv."},{"key":"10.1016\/j.jneumeth.2022.109581_bib59","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneumeth.2022.109581_bib60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.trci.2018.01.003","article-title":"Measuring cognition and function in the preclinical stage of Alzheimeras disease","volume":"4","author":"Weintraub","year":"2018","journal-title":"Alzheimer Dement.: Transl. Res. Clin. Interv."},{"key":"10.1016\/j.jneumeth.2022.109581_bib61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1037\/0894-4105.22.4.531","article-title":"The measurement of everyday cognition (ECog): scale development and psychometric properties","volume":"22","author":"Farias","year":"2008","journal-title":"Neuropsychology"},{"key":"10.1016\/j.jneumeth.2022.109581_bib62","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jalz.2014.09.002","article-title":"Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimeras disease","volume":"11","author":"Rueda","year":"2015","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.jneumeth.2022.109581_bib63","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1017\/S1355617715000818","article-title":"Early cognitively-based functional limitations predict loss of independence in instrumental activities of daily living in older adults","volume":"21","author":"Lau","year":"2015","journal-title":"J. Int. Neuropsychol. Soc.: JINS"},{"key":"10.1016\/j.jneumeth.2022.109581_bib64","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3233\/JAD-140843","article-title":"Biomarkers for preclinical Alzheimeras disease","volume":"42","author":"Tan","year":"2014","journal-title":"J. Alzheimer Dis."},{"key":"10.1016\/j.jneumeth.2022.109581_bib65","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fbioe.2015.00054","article-title":"Network neurodegeneration in Alzheimeras disease via MRI based shape diffeomorphometry and high-field atlasing","volume":"3","author":"Miller","year":"2015","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jneumeth.2022.109581_bib66","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fnagi.2016.00092","article-title":"The biomarkers for identifying preclinical Alzheimeras disease via structural and functional magnetic resonance imaging","volume":"8","author":"Zhou","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jneumeth.2022.109581_bib67","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.nicl.2014.04.009","article-title":"Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimeras disease","volume":"5","author":"Younes","year":"2014","journal-title":"NeuroImage: Clin."},{"key":"10.1016\/j.jneumeth.2022.109581_bib68","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/cpt.1166","article-title":"A novel method to estimate long-term chronological changes from fragmented observations in disease progression","volume":"105","author":"Ishida","year":"2019","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Journal of Neuroscience Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016502702200108X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016502702200108X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:02:22Z","timestamp":1759021342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016502702200108X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":68,"alternative-id":["S016502702200108X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneumeth.2022.109581","relation":{},"ISSN":["0165-0270"],"issn-type":[{"value":"0165-0270","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Categorical predictive and disease progression modeling in the early stage of Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroscience Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneumeth.2022.109581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109581"}}